Oct 31, 2023 / 01:00PM GMT
Carlos de Sousa - Ultimovacs ASA - CEO
Good afternoon, everybody, and welcome to the Ultimovacs webcast. During this webcast, we will be talking about the results from the NIPU trial that was just recently presented at ESMO, but also a little bit about the press release we had this morning on our second trial, the INITIUM trial, and some of the changes we implemented there.
As you all know, we had some, like many other companies in Madrid, had problems with a lot of streaming due to the bandwidth. So we are taking this opportunity to address some of the topics that we covered there, but also take the opportunity to talk about some of the questions -- the topics that we have been receiving so far.
So I have to say that these are very, very exciting times for cancer patients, but also for companies working in the space of cancer vaccines. We have now two companies that, for the first time, have shown in randomized competitive trials that cancer vaccines work. One of those companies, Moderna, with their individualized vaccine, has shown that in a study that they did in melanoma patients,
Ultimovacs ASA to Discuss the NIPU Study Results Call Transcript
Oct 31, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers